ASCO 2020

Yazar: Bartsch, Rupert, Dieras, Veronique, Cortes, Javier, Müller, Volkmar, Ruhstaller, Thomas
Yayımlandı Breast Care (Basel) (2020)

Expert Discussion: Highlights from the San Antonio Breast Cancer Symposium, San Antonio, December 8–11, 2020

Yazar: Müller, Volkmar, Dieras, Veronique, Cardoso, Fatima, Cameron, David, Cortes, Javier
Yayımlandı Breast Care (Basel) (2021)

Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic H...

Yazar: Paracha, Noman, Reyes, Adriana, Diéras, Véronique, Krop, Ian, Pivot, Xavier, Urruticoechea, Ander
Yayımlandı Breast Cancer Res Treat (2020)

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib

Yazar: Zheng, Jenny, Yu, Yanke, Durairaj, Chandrasekar, Diéras, Véronique, Finn, Richard S., Wang, Diane D.
Yayımlandı Target Oncol (2020)

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall...

Yazar: Diéras, Véronique, Miles, David, Verma, Sunil, Pegram, Mark, Welslau, Manfred, Baselga, José, Krop, Ian E, Blackwell, Kim, Hoersch, Silke, Xu, Jin, Green, Marjorie, Gianni, Luca
Yayımlandı Lancet Oncol (2017)

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer

Yazar: Bernadou, Guillemette, Campone, Mario, Merlin, Jean‐Louis, Gouilleux‐Gruart, Valérie, Bachelot, Thomas, Lokiec, François, Rezai, Keyvan, Arnedos, Monica, Diéras, Véronique, Jimenez, Marta, Paintaud, Gilles, Ternant, David
Yayımlandı Br J Clin Pharmacol (2016)

Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial

Yazar: Diéras, Véronique, Harbeck, Nadia, Joy, Anil Abraham, Gelmon, Karen, Ettl, Johannes, Verma, Sunil, Lu, Dongrui R., Gauthier, Eric, Schnell, Patrick, Mori, Ave, Rugo, Hope S., Finn, Richard S.
Yayımlandı Oncologist (2019)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours

Yazar: Wilson, Richard H, Evans, TR Jeffry, Middleton, Mark R, Molife, L Rhoda, Spicer, James, Dieras, Veronique, Roxburgh, Patricia, Giordano, Heidi, Jaw-Tsai, Sarah, Goble, Sandra, Plummer, Ruth
Yayımlandı Br J Cancer (2017)

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated...

Yazar: Sabatier, Renaud, Diéras, Véronique, Pivot, Xavier, Brain, Etienne, Roché, Henri, Extra, Jean-Marc, Monneur, Audrey, Provansal, Magali, Tarpin, Carole, Bertucci, François, Viens, Patrice, Zemmour, Christophe, Gonçalves, Anthony
Yayımlandı Cancer Res Treat (2018)

ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

Yazar: Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Yayımlandı Future Oncol (2019)

A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study

Yazar: Diéras, Véronique, Bachelot, Thomas, Campone, Mario, Isambert, Nicolas, Joly, Florence, Le Tourneau, Christophe, Cassier, Philippe, Bompas, Emmanuelle, Fumoleau, Pierre, Noal, Sabine, Orsini, Christine, Jimenez, Marta, Imbs, Diane Charlotte, Chatelut, Etienne
Yayımlandı Oncol Ther (2016)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

Yazar: Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Baskı/Yayın Bilgisi 2012

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

Yazar: Reyal, Fabien, Bollet, Marc A., Caly, Martial, Gentien, David, Carpentier, Sabrina, Peyro-Saint-Paul, Hélène, Pierga, Jean-Yves, Cottu, Paul, Dieras, Véronique, Sigal-Zafrani, Brigitte, Vincent-Salomon, Anne, Sastre-Garau, Xavier
Baskı/Yayın Bilgisi 2012

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

Yazar: Verma, Sunil, Miles, David, Gianni, Luca, Krop, Ian E., Welslau, Manfred, Baselga, José, Pegram, Mark, Oh, Do-Youn, Diéras, Véronique, Guardino, Ellie, Fang, Liang, Lu, Michael W., Olsen, Steven, Blackwell, Kim
Yayımlandı N Engl J Med (2012)

Longitudinal serum metabolomics evaluation of trastuzumab and everolimus combination as pre-operative treatment for HER-2 positive breast cancer patients

Yazar: Jobard, Elodie, Trédan, Olivier, Bachelot, Thomas, Vigneron, Arnaud M., Aït-Oukhatar, Céline Mahier, Arnedos, Monica, Rios, Maria, Bonneterre, Jacques, Diéras, Véronique, Jimenez, Marta, Merlin, Jean-Louis, Campone, Mario, Elena-Herrmann, Bénédicte
Yayımlandı Oncotarget (2017)

Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer

Yazar: Diéras, Véronique, Rugo, Hope S, Schnell, Patrick, Gelmon, Karen, Cristofanilli, Massimo, Loi, Sherene, Colleoni, Marco, Lu, Dongrui R, Mori, Ave, Gauthier, Eric, Huang Bartlett, Cynthia, Slamon, Dennis J, Turner, Nicholas C, Finn, Richard S
Yayımlandı J Natl Cancer Inst (2018)

MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2− metastatic breast cancer

Yazar: Dickler, Maura N., Tolaney, Sara M., Rugo, Hope S., Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A., O’Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A., Frenzel, Martin, Koustenis, Andrew, Baselga, José
Yayımlandı Clin Cancer Res (2017)

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers

Yazar: Hatem, Rana, Botty, Rania El, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta
Yayımlandı Oncotarget (2016)

NT-23 PHASE 1/2A STUDY OF GLUTATHIONE PEGYLATED LIPOSOMAL DOXORUBICIN (2B3-101) IN BREAST CANCER PATIENTS WITH BRAIN METASTASES (BCBM) OR RECURRENT HIGH GRADE GLIOMAS (HGG)

Yazar: Kerklaan, Bojana Milojkovic, Jager, Agnes, Aftimos, Philippe, Dieras, Veronique, Altintas, Sevilay, Anders, Carey, Arnedos, Monica, Gelderblom, Hans, Soetekouw, Patricia, Gladdines, Werner, Gaillard, Pieter, de Sousa, Carlos, Awada, Ahmad, Schellens, Jan, van Linde, Myra, Brandsma, Dieta
Baskı/Yayın Bilgisi 2014

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rati...

Yazar: Isakoff, Steven J, Puhalla, Shannon, Domchek, Susan M, Friedlander, Michael, Kaufman, Bella, Robson, Mark, Telli, Melinda L, Diéras, Véronique, Han, Hyo Sook, Garber, Judy E, Johnson, Eric F, Maag, David, Qin, Qin, Giranda, Vincent L, Shepherd, Stacie P
Yayımlandı Future Oncol (2017)